The earnings call presented several positive developments, including significant revenue growth, progress in clinical trials, and promising preclinical results. However, these were balanced by challenges such as workforce reductions, CFO resignation, and the risk of NASDAQ delisting. The sentiment is balanced by both achievements and significant challenges.

Company Guidance -

Q2 2025

During the Vaxart Business Update and First Quarter 2025 Financial Results Conference Call, guidance was provided on multiple fronts. The company announced that it is actively screening patients for its Project NextGen Phase 2b COVID-19 vaccine trial, with dosing expected to begin in the second quarter of 2025. This trial is supported by a BARDA contract worth up to $460.7 million. Additionally, Vaxart completed enrollment in a Phase 1 trial for its norovirus vaccine, with top-line data anticipated in mid-2025. Financially, the company reported a revenue increase to $20.9 million for Q1 2025, up from $2.2 million in Q1 2024, primarily due to the BARDA contract. Vaxart ended the quarter with $41.9 million in cash and expects its cash runway to extend into Q1 2026, despite recent workforce reductions aimed at cost rationalization. The company is also exploring strategic partnerships and non-dilutive funding to maintain its financial position while navigating the biotech environment.

Revenue Increase

Revenue for the first quarter of 2025 was $20.9 million, compared to $2.2 million for the first quarter of 2024, primarily due to the BARDA contract.

Lifting of Stop Work Order

The stop work order on the 10,000 participant portion of the COVID-19 Phase 2b clinical trial was lifted, allowing the trial to proceed.

Norovirus Vaccine Trial Progress

Completed enrollment of the Phase 1 trial for the second-generation norovirus vaccine candidate, with top-line data expected mid-2025.

Positive Preclinical Results in Avian Flu Program

Preclinical studies show 100% protection against death in a ferret model for the avian flu vaccine candidate.

Vaxart (VXRT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VXRT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.09 / -	-0.09	―	―	―
May 13, 2025	2025 (Q1)	-0.10 / -0.07	-0.14	50.00% (+0.07)	―
Mar 20, 2025	2024 (Q4)	-0.10 / -0.04	-0.11	63.64% (+0.07)	―
Nov 13, 2024	2024 (Q3)	-0.10 / -0.06	-0.11	45.45% (+0.05)	―
Aug 08, 2024	2024 (Q2)	-0.15 / -0.09	-0.16	43.75% (+0.07)	―
May 13, 2024	2024 (Q1)	-0.14 / -0.14	-0.19	26.32% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.13 / -0.11	-0.18	38.89% (+0.07)	―
Nov 02, 2023	2023 (Q3)	-0.18 / -0.11	-0.23	52.17% (+0.12)
Aug 03, 2023	2023 (Q2)	-0.18 / -0.16	-0.23	30.43% (+0.07)	―
May 04, 2023	2023 (Q1)	-0.19 / -0.19	-0.2	5.00% (+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VXRT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$0.42	$0.40	-4.76%
Mar 20, 2025	$0.57	$0.52	-8.77%
Nov 13, 2024	$0.71	$0.63	-11.27%
Aug 08, 2024	$0.63	$0.58	-7.94%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vaxart (VXRT) report earnings?

Vaxart (VXRT) is schdueled to report earning on Aug 13, 2025, TBA (Confirmed).

What is Vaxart (VXRT) earnings time?

Vaxart (VXRT) earnings time is at Aug 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VXRT EPS forecast?

VXRT EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing